Identifying safety concerns from genetic data: lessons from the development of CCR5 inhibitors.
Telenti
Amalio
A
Egger
Matthias
M
D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000235:genetics; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes / Q000009:adverse effects*; D015195:Drug Design; D005838:Genotype; D023581:HIV Fusion Inhibitors / Q000009:adverse effects*; D015658:HIV Infections / Q000188:drug therapy / Q000235:genetics; D006526:Hepatitis C / Q000139:chemically induced / Q000235:genetics; D006801:Humans; D000077592:Maraviroc; D015201:Meta-Analysis as Topic; D009103:Multiple Sclerosis / Q000139:chemically induced / Q000235:genetics; D009154:Mutation; D010597:Pharmacogenetics / Q000379:methods*; D019713:Receptors, CCR5 / Q000235:genetics* / Q000378:metabolism; D012107:Research Design; D018570:Risk Assessment; D012307:Risk Factors; D014230:Triazoles / Q000009:adverse effects*
D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D023581:HIV Fusion Inhibitors; D019713:Receptors, CCR5; D014230:Triazoles; D000077592:Maraviroc